Q2 2024 Treace Medical Concepts Inc Earnings Call Transcript
Key Points
- Treace Medical Concepts Inc (TMCI) reported second-quarter revenue of $44.5 million, representing a 6% growth over the same period in 2023.
- The company is actively expanding its product line with more than 10 new products expected to be commercialized starting in the back half of 2024 and throughout 2025.
- Treace Medical Concepts Inc (TMCI) is leveraging its Lapiplasty market leadership to enter the minimally invasive osteotomy market, which is gaining interest among doctors and patients.
- The company has a strong R&D pipeline and is committed to delivering new technologies to penetrate the $5 billion-plus US bunion market.
- Treace Medical Concepts Inc (TMCI) is reaffirming its full-year 2024 revenue guidance of $201 million to $211 million, reflecting an increase of 7% to 13% over 2023 revenue.
- Gross margin decreased to 80.2% in the second quarter of 2024 from 81.7% in the same period of 2023, primarily due to changes in product mix and increased costs.
- The company reported a net loss attributable to common stockholders of $21.3 million or $0.34 per share, compared to a net loss of $12.4 million or $0.20 per share in the same period of 2023.
- Operating expenses increased to $57.1 million in the second quarter of 2024 from $47.3 million in the same period of 2023, reflecting strategic investments in sales and product innovation.
- The minimally invasive osteotomy market remains technically challenging, with a steep learning curve for surgeons, potentially limiting adoption.
- The proposed Medicare reimbursement rates for 2025, while encouraging, are not yet finalized and could change, impacting future financial outcomes.
Good day, and thank you for standing by. Welcome to the Treace Medical Concepts second-quarter 2024 earnings conference call. (Operator Instruction) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Vivian Cervantes, Gilmartin, Investor Relations. Please go ahead.
Good afternoon, everyone, and welcome to our second-quarter 2024 earnings conference call. Participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer. During the call, John will offer commentary on our commercial activities, followed by Mark for a detailed review of our second-quarter financial results released after market closed today.
We will host a question-and-answer session following our prepared remarks. Our press release can be found in the Investor Relations section of our website at investors.treace.com. This call is being recorded and will be archived in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
